Advanced search
Publication Cover
Cell Cycle Volume 16, 2017 - Issue 6
Submit an article Journal homepage
956
Views
16
CrossRef citations to date
0
Altmetric
Report

Expression profile of SIRT2 in human melanoma and implications for sirtuin-based chemotherapy

Melissa Jean Wilking-BuschDepartment of Dermatology, University of Wisconsin, Madison, WI, USA
,
Mary Ann NdiayeDepartment of Dermatology, University of Wisconsin, Madison, WI, USA
,
Wei HuangDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA
&
Nihal AhmadDepartment of Dermatology, University of Wisconsin, Madison, WI, USA;William S. Middleton VA Medical Center, Madison, WI, USACorrespondence[email protected],
Pages 574-577 | Received 14 Nov 2016, Accepted 24 Jan 2017, Published online: 27 Feb 2017

References

  • Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67(1):7-30; http://dx.doi.org/10.3322/caac.21387
  • Mavropoulos JC, Wang TS. Managing the skin toxicities from new melanoma drugs. Curr Treat Options Oncol 2014; 15(2):281-301; PMID: 24867225; http://dx.doi.org/10.1007/s11864-014-0284-6
  • Peuvrel L, Quereux G, Saint-Jean M, Brocard A, Nguyen JM, Khammari A, Knol AC, Varey E, Dreno B. Profile of vemurafenib-induced severe skin toxicities. J Eur Acad Dermatol Venereol 2016; 30(2):250-7; PMID: 26524690; http://dx.doi.org/10.1111/jdv.13443
  • McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15(3):323-32; PMID: 24508103; http://dx.doi.org/10.1016/S1470-2045(14)70012-9
  • Spagnolo F, Ghiorzo P, Queirolo P. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014; 5(21):10206-21; PMID: 25344914; http://dx.doi.org/10.18632/oncotarget.2602
  • Shore D, Squire M, Nasmyth KA. Characterization of two genes required for the position-effect control of yeast mating-type genes. EMBO J. 1984; 3(12):2817-23; PMID: 6098447
  • Costantini S, Sharma A, Raucci R, Costantini M, Autiero I, Colonna G. Genealogy of an ancient protein family: the Sirtuins, a family of disordered members. BMC Evol Biol 2013; 13:60; PMID: 23497088
  • Osborne B, Bentley NL, Montgomery MK, Turner N. The role of mitochondrial sirtuins in health and disease. Free Radic Biol Med 2016; pii: S0891-5849(16):30217-9
  • Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 2013; 6:1399-416
  • Bedalov A, Chowdhury S, Simon JA. Biology, Chemistry, and Pharmacology of Sirtuins. Methods Enzymol 2016; 574:183-211; PMID: 27423863
  • Singh CK, George J, Nihal M, Sabat G, Kumar R, Ahmad N. Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach. Oncotarget 2014; 5(7):1987-99; PMID: 24743044; http://dx.doi.org/10.18632/oncotarget.1898
  • Wilking MJ, Singh C, Nihal M, Zhong W, Ahmad N. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys 2014; 563:94-100; PMID: 24751483
  • Wilking MJ, Singh CK, Nihal M, Ndiaye MA, Ahmad N. Sirtuin deacetylases: a new target for melanoma management. Cell Cycle 2014; 13(18):2821-6; PMID: 25486469; http://dx.doi.org/10.4161/15384101.2014.949085
  • Zhang Y, Au Q, Zhang M, Barber JR, Ng SC, Zhang B. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem Biophys Res Commun 2009; 386(4):729-33; PMID: 19559674; http://dx.doi.org/10.1016/j.bbrc.2009.06.113
  • Bajpe PK, Prahallad A, Horlings H, Nagtegaal I, Beijersbergen R, Bernards R. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene 2015; 34(4):531-6; PMID: 24469059; http://dx.doi.org/10.1038/onc.2013.588
  • Halfed DG, Zoroquiain P, Wood HA, Blanco P, Al-Saati N, Aldrees S, Bravo-Filho V, Burnier MN. SIRT2 Expression Is Higher in Uveal Melanoma than In Ocular Melanocytes. Ocul Oncol Pathol 2015; 2(2):100-4; PMID: 27171429; http://dx.doi.org/10.1159/000439309

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.